Biblio
Export 550 results:
[ Author] Title Type Year Filters: Keyword is Alzheimer Disease [Clear All Filters]
“Tau in Alzheimer disease and related tauopathies.”, Curr Alzheimer Res, vol. 7, no. 8, pp. 656-64, 2010.
, “Computational Evaluation of Azadirachta indica-Derived Bioactive Compounds as Potential Inhibitors of NLRP3 in the Treatment of Alzheimer's Disease.”, J Alzheimers Dis, vol. 94, no. s1, pp. S67-S85, 2023.
, “Role of Suppressor of Cytokine Signaling 3 (SOCS3) in Altering Activated Microglia Phenotype in APPswe/PS1dE9 Mice.”, J Alzheimers Dis, vol. 55, no. 3, pp. 1235-1247, 2017.
, “Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers.”, Lancet Neurol, vol. 12, no. 2, pp. 207-16, 2013.
, “An operational approach to National Institute on Aging-Alzheimer's Association criteria for preclinical Alzheimer disease.”, Ann Neurol, vol. 71, no. 6, pp. 765-75, 2012.
, “Evidence for ordering of Alzheimer disease biomarkers.”, Arch Neurol, vol. 68, no. 12, pp. 1526-35, 2011.
, “It's Groundhog Day! What Can the History of Science Say About the Crisis in Alzheimer's Disease Research?”, J Alzheimers Dis, vol. 90, no. 4, pp. 1401-1415, 2022.
, “Medial Temporal Lobe Atrophy in Predementia Alzheimer's Disease: A Longitudinal Multi-Site Study Comparing Staging and A/T/N in a Clinical Research Cohort.”, J Alzheimers Dis, vol. 94, no. 1, pp. 259-279, 2023.
, “The Vanderbilt Memory & Aging Project: Study Design and Baseline Cohort Overview.”, J Alzheimers Dis, vol. 52, no. 2, pp. 539-59, 2016.
, “Cognitive Function Associated with Gut Microbial Abundance in Sucrose and S-Adenosyl-L-Methionine (SAMe) Metabolic Pathways.”, J Alzheimers Dis, vol. 87, no. 3, pp. 1115-1130, 2022.
, “A 19-Year-Old Adolescent with Probable Alzheimer's Disease.”, J Alzheimers Dis, vol. 91, no. 3, pp. 915-922, 2023.
, “Soluble amyloid beta-protein dimers isolated from Alzheimer cortex directly induce Tau hyperphosphorylation and neuritic degeneration.”, Proc Natl Acad Sci U S A, vol. 108, no. 14, pp. 5819-24, 2011.
, “Dementia Apraxia Test (DATE): A Brief Tool to Differentiate Behavioral Variant Frontotemporal Dementia from Alzheimer's Dementia Based on Apraxia Profiles.”, J Alzheimers Dis, vol. 49, no. 3, pp. 593-605, 2016.
, “Genetic evidence implicates the immune system and cholesterol metabolism in the aetiology of Alzheimer's disease.”, PLoS One, vol. 5, no. 11, p. e13950, 2010.
, “A mutation in APP protects against Alzheimer's disease and age-related cognitive decline.”, Nature, vol. 488, no. 7409, pp. 96-9, 2012.
, “When Art Meets Gardens: Does It Enhance the Benefits? The Nancy Hypothesis of Care for Persons with Alzheimer's Disease.”, J Alzheimers Dis, vol. 61, no. 3, pp. 885-898, 2018.
, “Medial Temporal Atrophy in Posterior Cortical Atrophy and Its Relationship to the Cingulate Island Sign.”, J Alzheimers Dis, vol. 86, no. 1, pp. 491-498, 2022.
, “Altered Affective Evaluations of Smells in Alzheimer's Disease.”, J Alzheimers Dis, vol. 49, no. 2, pp. 433-41, 2016.
, “Pathogenic protein seeding in Alzheimer disease and other neurodegenerative disorders.”, Ann Neurol, vol. 70, no. 4, pp. 532-40, 2011.
, “Disrupted energy metabolism and neuronal circuit dysfunction in cognitive impairment and Alzheimer's disease.”, Lancet Neurol, vol. 10, no. 2, pp. 187-98, 2011.
, “Blood Tests for Alzheimer's Disease: Increasing Efforts to Expand and Diversify Research Participation Is Critical for Widespread Validation and Acceptance.”, J Alzheimers Dis, vol. 90, no. 3, pp. 967-974, 2022.
, “Low Prevalence of Cancer in Patients with Frontotemporal Lobar Degeneration.”, J Alzheimers Dis, vol. 62, no. 2, pp. 789-794, 2018.
, “Psychopharmacological Medication Use in Frontotemporal Dementia at the Time of Diagnosis: Comparison with Alzheimer's Disease.”, J Alzheimers Dis, vol. 95, no. 2, pp. 677-685, 2023.
, “The Rationale and Design of the Reducing Pathology in Alzheimer's Disease through Angiotensin TaRgeting (RADAR) Trial.”, J Alzheimers Dis, vol. 61, no. 2, pp. 803-814, 2018.
, “Post Hoc Analyses of ApoE Genotype-Defined Subgroups in Clinical Trials.”, J Alzheimers Dis, vol. 50, no. 4, pp. 1205-15, 2016.
,